Portfolio company
Umoja Biopharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops in vivo cell therapies to treat oncology and autoimmunity patients by generating chimeric antigen receptor T cells inside the body.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
Orca Bio
This company develops high-precision allogeneic cell therapies to treat patients with blood cancers and autoimmune diseases by replacing diseased immune systems with donor cells.
Azalea Therapeutics
The company develops in vivo genome editing therapies to engineer T cells directly inside the body for patients with cancer and autoimmune diseases.
Arcellx
This biotechnology company develops cell therapies to treat patients with cancer and autoimmune diseases.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Swarm Oncology
This biotechnology company develops personalised T cell therapies for patients with advanced solid cancers to achieve long-term remission.
Cabaletta Bio
This clinical-stage biotechnology company develops engineered T cell therapies for patients with various autoimmune diseases.
Vittoria Biotherapeutics
This company develops engineered T-cell therapies for patients with cancer and immunological disorders using its proprietary cell manufacturing platform.
